Wasatch Advisors owns 4.7% of C4 Therapeutics
C4 Therapeutics Inc Schedule 13G/A amendment shows Wasatch Advisors beneficially owned 4,581,761 shares of common stock, representing 4.7% of the class as reported.
Rhea-AI Filing Summary
C4 Therapeutics Inc Schedule 13G/A amendment shows Wasatch Advisors beneficially owned 4,581,761 shares of common stock, representing 4.7% of the class as reported. The filing lists sole voting and sole dispositive power over the same 4,581,761 shares. Signature date is 04/22/2026.
Positive
- None.
Negative
- None.
Insights
Wasatch holds a sub-5% passive stake in C4 Therapeutics.
Wasatch Advisors reports beneficial ownership of 4,581,761 shares, equal to 4.7% of common stock with sole voting and dispositive power. This places Wasatch below the 5% threshold that often distinguishes Schedule 13G from 13D reporting dynamics.
Institutional holdings at this level are a common ownership disclosure; subsequent filings would show increases or decreases. Changes in stake size or additional disclosures would appear in future amendments.
Key Figures
Key Terms
Schedule 13G/A regulatory
Beneficially owned financial
Sole dispositive power regulatory
FAQ
What stake does Wasatch Advisors report in C4 Therapeutics (CCCC)?
Which filing reports Wasatch Advisors' ownership of C4 Therapeutics?
What voting and disposition rights does Wasatch hold?
As of what date is the ownership reported?
Does the Schedule 13G/A indicate Wasatch intends to change its position?
AI-generated analysis. How Rhea-AI works. Not financial advice.